ClinicalTrials.gg
RecruitingNCT07726446Updated Jul 24, 2026

Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors

A Phase 2 interventional study of PD-1 and chemotherapy and cryoablation in Biliary Tract Cancer (BTC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies testing Immune checkpoint inhibitors in Biliary Tract Neoplasms — 48 open to participants now, 67 under way, 8 of them phase 3. A drug class: Immune checkpoint inhibitors · Biliary Tract Neoplasms.

Planned enrollment
74th of 105
30 · median 44
Started
2026
with 16 others
Phase 2
77 of 105
37 open now
Primary completion
2027-10
later than 44 of 66 live
Registered
100th of 105
by date
Lead sponsor
6 of 105
Tianjin Medical University Cancer Institute and Hospital

Among the 105 studies testing Immune checkpoint inhibitors in Biliary Tract Neoplasms, this one is the 74th largest by planned enrollment, is one of 17 that started in 2026, is one of 77 in phase 2, reaches primary completion later than 44 of the 66 other live ones, and was the 100th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

48 of the 105 studies testing Immune checkpoint inhibitors in Biliary Tract Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

42 more — sign in →

By country, each count listing its studies:

All 48 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies testing Immune checkpoint inhibitors in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, single-arm, open-label Phase II clinical trial, planned to enroll 30 patients with unresectable locally advanced or metastatic iCCA/GBC. Patients will first receive cryoablation treatment, and two weeks after ablation, they will receive 8 cycles of immunotherapy combined with chemotherapy (Relatlimab α plus GC chemotherapy, every 3 weeks). During the maintenance phase, patients will continue with Relatlimab α alone, every 3 weeks, for up to one year. During the combination treatment phase, efficacy will be evaluated every 6 weeks, and during the maintenance phase, every 6 to 9 weeks. From the date of randomization/enrollment, survival follow-ups will be conducted every 3 months (±14 days) for the first 2 years; afterwards, follow-ups will occur every 6 months (±28 days) until the participant dies, is lost to follow-up, or the study ends, whichever comes first.

03

Conditions studied

  • Biliary Tract Cancer (BTC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, any gender;
  2. confirmed unresectable locally advanced/ intrahepatic cholangiocarcinoma or gallbladder cancer;
  3. No prior anti-tumor treatment;
  4. At least one measurable target lesion according to 1.1 tumor evaluation criteria, and at least one lesion suitable for ablation;
  5. No active disease;
  6. No concurrent ;
  7. performance status 0-1;
  8. Expected survival ≥ 3 months;
  9. Adequate organ and bone marrow function (no transfusion, recombinant human thrombopoietin, or colony-stimulating factor treatment within 2 weeks before first dose), defined as:

    1. Blood count: neutrophils (NEUT) ≥ 1.2×10\^9/L; (PLT) ≥ 90×10\^9/L; ≥ 90 g/dL;
    2. Liver function: and ALT ≤ 2.5× (ULN); ALP ≤ 2.5×ULN; total (TBIL) ≤ 1.5×ULN; if liver metastases, ALT and AST ≤ 5×ULN;
    3. ≤ 1.25;
    4. Serum creatinine ≤ 1.5× ULN or (CrCl) ≥ 30 mL/min (using Cockcroft-Gault formula);
  10. Female participants of and male participants with partners of childbearing potential must agree to use effective medical from signing the until 6 months after the last dose;
  11. Participants voluntarily join the study, sign the informed consent form, and can comply with scheduled visits and related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Previously received systemic anti-tumor treatment;
  2. Active ; patients with asymptomatic brain metastases can be enrolled; for patients clinically suspected of central nervous system , a CT or MRI must be performed within 28 days before enrollment to rule out central nervous system metastasis;
  3. Had other malignant tumors within 5 years before administration (except tumors cured with radical treatment, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, etc.);
  4. Allergic to the study drug (Rilafup Alpha Injection, or other );
  5. History of unstable angina; newly diagnosed angina within 3 months before screening or myocardial infarction within 6 months before screening; arrhythmias (including : men ≥ 450 ms, women ≥ 470 ms) requiring long-term use of anti-arrhythmic drugs and class ≥ II heart failure;
  6. Urinalysis showing protein ≥ and confirmed 24-hour urine protein quantification > 1.0g;
  7. Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia, or other conditions requiring therapy; history of chronic diseases, such as systemic lupus erythematosus; history of ulcerative colitis, Crohn's disease, or other inflammatory bowel diseases; history of chronic diarrhea conditions like irritable bowel syndrome; history of sarcoidosis or tuberculosis; active or C, and infection;
  8. Currently participating in interventional clinical research treatment, or have received other study drugs or devices within 4 weeks before first administration;
  9. History of substance abuse that cannot be stopped or mental disorders; Any other situation in which the investigator believes the patient is not suitable for participation in this study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ablation combined with chemo and immunotherapy

    Drug: PD-1 and chemotherapy · Procedure: cryoablation

Interventions

  • DrugPD-1 and chemotherapy

    Drug page: Immune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rilapafup α: 1800 mg, intravenous infusion, every 3 weeks. Use Rilapafup α injection (same dose as above) for maintenance therapy until disease progression or unacceptable toxicity occurs. Chemotherapy: Gemcitabine 1000 mg/m² IV infusion over 30 minutes on days 1 and 8; Cisplatin 25 mg/m² IV infusion on days 1 and 8; repeat every 3 weeks.

  • Procedurecryoablation

    Cryoablation: Depending on the size and location of the tumor, a cryoprobe is inserted percutaneously into the center of the tumor under ultrasound guidance. Once the probe is in place, the tip is cooled down to -196℃, freezing the tumor for 15 minutes, then warmed up (to about 80℃) for 5 minutes, completing two freeze-thaw cycles.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    ORR

    Time frame: 1 year

Secondary outcomes

  1. Objective response rate in the subgroup

    Time frame: 1 year

  2. disease control rate

    Time frame: 1 year

  3. Progression-free survival

    Time frame: 2 years

  4. Overall survival

    Time frame: 2 years

  5. Duration of Response

    Time frame: 1 year

  6. mRECIST standard evaluation of objective response rate

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Tianqiang T Song, MD · Contacttjchi@hotmail.com · 18622221077
    • Liyu L Sun · Contact17860489096
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 12 months is below that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 24, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2030
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07726446
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jul 24, 2026

Study contacts

Tianqiang T Song, MD
Contact
tjchi@hotmail.com
18622221077
Liyu L Sun
Contact
17860489096

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immune checkpoint inhibitors

Start the discussion